Back

KRASG12C Inhibition Remodels the Non-Small Cell Lung Cancer Surfaceome to Uncover Targetable Vulnerabilities

Padhye, A.; Kang, K.; Kong, F. Y.; Sindoni, N.; Yu, Q.; Jiang, B.; Chang, W.-H.; Coker, O.; Kim, E.; Dilly, J.; Shin, M.; Paulo, J. A.; Sprouffske, K.; Brachmann, S. M.; Stalnecker, C. A.; Aguirre, A. J.; Mancias, J. D.

2026-10-02 cancer biology
10.64898/2026.10.01.756013 bioRxiv
Show abstract

Mutant-selective and pan-RAS(ON) multi-selective inhibitors have improved clinical outcomes for patients with RAS-driven cancers; however, adaptive resistance limits the depth and durability of response. Using an integrated genetic, transcriptomic, and mass-spectrometry-based quantitative temporal proteomic platform, we profile the adaptive response to KRASG12C inhibitors (KRASi) in KRASG12C-mutant lung adenocarcinoma models. Our analyses reveal remodeling of signaling pathways and the cell surface proteome, including cell surface proteins selectively upregulated across cell lines, tumor models, and treatment durations. Folate receptor alpha (FOLR1) emerged as a therapeutically actionable target that is significantly upregulated with KRASi and is part of a broader acute cellular state transition characterized by acquisition of an epithelial identity. Combining KRASi with mirvetuximab soravtansine-gynx, a clinically approved FOLR1-targeting antibody drug conjugate, enhanced tumor cell cytotoxicity and deepened response and tumor control in cellular and in vivo models. Additionally, this work represents a comprehensive multi-omic resource characterizing non-genetic temporal adaptation to KRASi for future mechanistic and therapeutic investigations.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Cancer Cell
○ 42 papers in training set
Top 0.1%
11.5%
Similar papers in this journal
2
Nature Communications
○ 5641 papers in training set
Top 17%
11.5%
Similar papers in this journal
3
Cell Reports Medicine
○ 153 papers in training set
Top 0.2%
6.5%
Similar papers in this journal
4
Cell Reports
○ 1498 papers in training set
Top 7%
5.3%
Similar papers in this journal
5
Molecular Systems Biology
○ 162 papers in training set
Top 0.4%
5.0%
Similar papers in this journal
6
Cancer Research
● 130 papers in training set
Top 1%
3.9%
7
Science Advances
● 1243 papers in training set
Top 9%
3.9%
8
Cancer Discovery
● 66 papers in training set
Top 0.8%
3.3%
50% of probability mass above
9
npj Precision Oncology
○ 53 papers in training set
Top 0.5%
3.1%
10
Genome Medicine
○ 183 papers in training set
Top 2%
3.1%
11
Nature Cancer
○ 39 papers in training set
Top 0.7%
2.3%
12
Molecular Cancer
○ 16 papers in training set
Top 0.1%
2.3%
13
Science Signaling
● 65 papers in training set
Top 0.6%
1.8%
14
EMBO Molecular Medicine
○ 95 papers in training set
Top 0.9%
1.7%
15
JCI Insight
● 277 papers in training set
Top 5%
1.4%
16
Nature Chemical Biology
○ 119 papers in training set
Top 2%
1.4%
17
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 33%
1.3%
18
Oncogene
○ 85 papers in training set
Top 1%
1.1%
19
Journal of Clinical Investigation
● 179 papers in training set
Top 5%
1.1%
20
eBioMedicine
○ 183 papers in training set
Top 5%
1.1%
21
Clinical Cancer Research
● 64 papers in training set
Top 2%
1.1%
22
Molecular Cell
○ 350 papers in training set
Top 4%
1.1%
23
Cell
○ 431 papers in training set
Top 9%
1.1%
24
eLife
● 5828 papers in training set
Top 63%
1.0%
25
Cell Chemical Biology
○ 94 papers in training set
Top 2%
0.8%
26
Molecular Cancer Research
● 49 papers in training set
Top 1%
0.8%
27
Advanced Science
○ 286 papers in training set
Top 10%
0.8%
28
Communications Medicine
○ 113 papers in training set
Top 5%
0.8%
29
iScience
○ 1154 papers in training set
Top 38%
0.8%
30
Cell Systems
○ 201 papers in training set
Top 5%
0.8%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.